Search Results - David Shamblaw

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate

    Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate by Gregory Huhn, David Shamblaw, Jean‐Guy Baril, Priscilla Y. Hsue, Brittany L Mills, Thai Nguyen-Cleary, Scott McCallister, Moupali Das

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

    Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil... by Calvin Cohen, Richard Elion, Peter Ruane, David Shamblaw, Edwin DeJesus, Bruce Rashbaum, Steven L. Chuck, Kitty Yale, Hui C. Liu, David R. Warren, S. Ramanathan, Brian P. Kearney

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

    Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppre... by Frank J. Palella, Martin Fisher, Pablo Tebas, Brian Gazzard, Peter Ruane, Jan van Lunzen, David Shamblaw, Jason Flamm, Ramin Ebrahimi, Danielle Porter, Kirsten L. White, Jason Hindman, Elizabeth Elbert, Shampa De-Oertel, Todd Fralich

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy

    Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy by Anthony Mills, Gordon Crofoot, Cheryl McDonald, Peter Shalit, Jason Flamm, Joseph Gathe, Anita Scribner, David Shamblaw, Michael S. Saag, Huyen Cao, Hal Martin, Moupali Das, Anne Thomas, Hui C. Liu, Mingjin Yan, Christian Callebaut, Joseph M. Custodio, Andrew Cheng, Scott McCallister

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

    Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-cont... by Anthony Mills, José Ramón Arribas, Jaime Andrade‐Villanueva, Giovanni DiPerri, Jan van Lunzen, Ellen Koenig, Richard Elion, Matthias Cavassini, Jose Valdez Madruga, Jason Brunetta, David Shamblaw, Edwin DeJesus, Chloe Orkin, David A. Wohl, Indira Brar, Jeffrey L. Stephens, Pierre-Marie Girard, Gregory Huhn, Andrew Plummer, Ya-Pei Liu, Andrew Cheng, Scott McCallister

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: